Portfolio companies

Hybridize therapeutics

Hybridize Therapeutics has spun out of the LUMC in 2019. Hybridize’s overarching goal is to help patients overcome untreated viral diseases by developing virus-specific RNA-based therapies, i.e. antisense oligonucleotides. They currently have a pipeline of two preclinical programs for BK-virus and SARS-CoV2 & JC-virus.


Stay up to date with news, inspirations and events.

© Starfish Innovations. All rights reserved.